Core Laboratories Cuts Q1 2026 Revenue Guidance to $119–123M, EPS to $0.05–0.07
Core Laboratories now expects Q1 2026 revenue of $119–123 million and ex-items EPS of $0.05–0.07, down from prior guidance. The revision reflects client-driven project delays, travel constraints and supply-chain disruptions affecting its Reservoir Description operations in the Middle East.
1. Q1 2026 Guidance Revision
Core Laboratories now expects first quarter 2026 revenue between $119 million and $123 million, down from prior guidance, with operating income ex-items of $5.7 million to $7.1 million and adjusted EPS of $0.05 to $0.07.
2. Geopolitical Disruption Effects
Regional instability in the Middle East has driven client-led project delays, travel restrictions and supply-chain disruptions, exacerbated by damage to refining infrastructure and logistical bottlenecks in and around the Strait of Hormuz.
3. Segment Impact Analysis
Reservoir Description operations were the most affected due to dependencies on field access, sample transport and laboratory work, while Production Enhancement saw fewer disruptions though shipments of certain energetics products were temporarily suspended.
4. Upcoming Earnings Webcast
The company will host its first quarter 2026 earnings webcast on April 30, 2026 at 7:30 a.m. CDT (8:30 a.m. EDT), with the accompanying press release to follow market close on April 29.